Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery of Semaglutide via RaniPill® HC
Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...
Websites selling compounded GLP-1 RAs often misinform consumers, research reveals
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to U.S. Food and Drug Administration approval, ...
Medscape17y
Nocturnal Hypoglycemia: Answering the Challenge With Long-acting Insulin Analogs
Subcutaneous glucagon administration is recommended if the hypoglycemic episode is suspected to be severe (ie, if the patient is asleep and cannot be aroused). [40] Convenient glucagon kits with ...
Rani Therapeutics announces data from semaglutide via RaniPill capsule trial
Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...
KSL11d
Study ties Ozempic-like drugs to dozens of benefits and risks
Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...
Medscape2d
Dipeptidyl Peptidase-4 Inhibitors: Clinical Data and Clinical Implications
The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 ... allowing once-daily administration. In drug-naïve subjects with type 2 diabetes, both ...
HealthDay on MSN15d
Websites Selling Compounded GLP-1 RAs Often Misinform Consumers
Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...